New drug discovery agreement
Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and inflammatory conditions. “We have been impressed by the depth of the BioFocus technology platforms, and the obvious strength and experience of the company’s scientists,” said Almirall CSO Bertil Lindmark. Under the terms of the collaboration, BioFocus will apply its screening technologies to an undisclosed number of Almirall projects. “We are delighted to form a drug discovery alliance with one of Europe’s leading research-based pharmaceutical companies,” added Kate Hilyard, BioFocus VP for Biological Sciences.